CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β … – GlobeNewswire (press release)
|
CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β …
GlobeNewswire (press release) “CRISPR Therapeutics is pioneering a new class of medicines with the CTA submission for CTX001 to conduct the first company-sponsored clinical trial of a CRISPR gene-edited therapy,” commented Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR … Canada's AmorChem launches $44.2M life science fund; Neon adds $36M, Merck partnership in neoantigen drive … Crispr Therapeutics (NASDAQ:CRSP) Getting Somewhat Favorable News Coverage, Study Finds Analyst Stock Ratings: CRISPR Therapeutics AG (CRSP), T2 Biosystems, Inc. (TTOO) |
